Dr. Harini Pal Bejjanki, MD

Dr. Bejjanki practices at College Park Dialysis in Houston, Texas.

Dr. Bejjanki's NPI, 1508152190, was assigned on June 22, 2011. Dr. Bejjanki graduated from Other in 2010. Dr. Bejjanki holds Texas license S6131.

Dr. Bejjanki's primary practice is College Park Dialysis, at 607 Timberdale Ln, Houston, TX 77090 in Harris County. The practice phone is (936) 273-3350.

Dr. Bejjanki's primary practice is College Park Dialysis in Houston, Texas. Dr. Bejjanki is also affiliated with Memorial Hermann Greater Heights Hospital. The medical group on file is Renal Physicians of Montgomery County, P.A. Dmand AI also links Dr. Bejjanki to 4 more hospitals, 5 dialysis centers, 3 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bejjanki practices, 13 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Bejjanki's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Bejjanki is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Bejjanki's licenses on file in 5 states: Texas, Florida, Washington, Arkansas and Michigan.

Dmand AI lists acute kidney failure, chronic kidney disease and fluid and electrolyte imbalances among the conditions Dr. Bejjanki treats.

CMS data shows 897 Medicare services from Dr. Bejjanki across 12 procedure codes in 2024, for 196 Medicare patients. Medicare paid $55,770 for them.

CMS counts 196 Medicare patients who saw Dr. Bejjanki in 2024. The largest group is 75 to 84, with 80 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 9% are also on Medicaid. Their average risk score is 3.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bejjanki's median patient age at 70, with 50% women.

In 2024, Dr. Bejjanki wrote 1,010 Medicare Part D claims for 221 patients. 90% of them were for generic drugs. CMS names the drug for 718 of them, across 24 drugs with 11 or more claims each, at $51,552 in total drug cost. In 2023, CMS named 416 claims across 17 drugs.

Dr. Bejjanki accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 20 papers to Dr. Bejjanki, published from 2018 to 2022. 2019 was the busiest year, with 8. The most frequent topics are Kidney Failure, Chronic, Ultrasonography and Anti-Bacterial Agents. Dr. Bejjanki has published most often in Am J Med. Dr. Bejjanki's most frequent co-authors are Abhilash Koratala, MD, Rohit Bishnoi, MD and Chintan Pareshbhai Shah, MD.

CMS Open Payments shows 67 general payments to Dr. Bejjanki from 20 drug and device companies from 2018 to 2025. Travel and lodging make up the largest share, 60% of the total. CSL Behring paid the most, $2,095.

Dr. Bejjanki graduated from Other in 2010.

Dr. Bejjanki is in network with 25 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 15. Check the plan with the practice before a visit.